Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from OTCQB

After Sundial, Cansortium, & YourWay Cannabis Brands, Other Marijuana Operators Also Delay Filing Earnings Reports

Several marijuana companies have postponed releasing their annual financial statements in the past months, and their number seems to be growing.

Benzinga

Psyence, Filament Strike Magic Mushroom Product Licensing Agreement: What You Need To Know

Psyence Group (OTCQB: PSYGF) and Filament Health Corp. (OTCQB: FLHLF) announced the signing of a licensing agreement: Filament is to license its proprietary psilocybin derived drug, PEX010, and the associated IP to

Benzinga

atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results

atai Life Sciences N.V. (NASDAQ:ATAI) has announced its financial results for the fourth quarter and full year ended December 31, 2021. 2021 Financial Results Highlights included: Positive Phase 2b data with COMP360 from a ground-breaking treatment-resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive impairment…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Psyched: Third Michigan City Decriminalizes Psychedelics, MindMed Reports $133M Cash Position, Real Brands To Enter The Space

The psychedelics legislative landscape continues to move forward with Hazel Park, Michigan enacting decriminalization measures for naturally-produced psychedelic molecules, becoming the third city in the state to do so after Ann Arbor and Detroit. In Utah, Governor Cox signed a psychedelics research bill into law and positive legislation around psilocybin is continuing…

Benzinga

Body And Mind Reports 27% YoY Revenue Growth In Q2, Positive Operational Cashflow

Body and Mind Inc. (CSE: BAMM) (OTCQB: BMMJ) has reported its financial results for the second fiscal quarter ended January 31, 2022.

Benzinga

APPlife Digital Solutions Completes Initial Phase Of LollipopNFT, User-Friendly Platform For NFTs

APPlife Digital Solutions, Inc (OTCQB: ALDS), a business incubator and portfolio manager that invests in and creates e-commerce and cloud-based solutions announced on Thursday that it has completed the important first stage of its all-inclusive, user-friendly non-fungible-token (NFT) platform

Benzinga

Panacea Launches CBD And CBG Skincare Products For Rosacea, Eczema, And Psoriasis Among Other Skin Conditions

Biotech cannabinoid company, Panacea Life Sciences, Inc. (OTCQB: PLSH), expanded its skincare line with innovative CBD and CBG formulations to help combat skin issues like acne, wrinkles, and even more severe conditions such as eczema and psoriasis.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Harvest One's Q2 Revenue Drops 10% YoY, Adjusted EBITDA Continues To Improve

Harvest One Cannabis Inc. (TSXV: HVT) (OTCQB: HRVOF) announced its fiscal second quarter and year-to-date financial and operating results for the three and six months ended December 31, 2021.

Benzinga

Sugarbud Reveals Preliminary Q4 Results, Record Revenue & Strong Quarterly Gross Profit

Sugarbud Craft Growers Corp. (TSXV: SUGR) (OTCQB: SBUDD) has announced its certain preliminary unaudited financial and operating results for the fourth quarter of 2021 and provided management comments regarding the copmany’s outlook for 2022.

Benzinga

PharmaDrug Posts Positive Results For DMT-Analogue Program To Treat Glaucoma

Psychedelics and cannabis-focused pharmaceutical company PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) has completed a head-to-head potency comparator study of its two undisclosed DMT-analogue candidates for the treatment of primary open angle glaucoma.

Benzinga

Tetra Bio-Pharma Signs License Agreement With Thorne Health Tech For A Prebiotic Dietary Supplement

Tetra Bio-Pharma Inc (TSX:TBP) (OTCQB: TBPMF) (FRA: JAM1), cannabinoid-based drug developer, has signed a licensing agreement with Thorne Health Tech, Inc. (NASDAQ: THRN) for the commercialization of its patent

Benzinga

Marijuana Producer Decibel Achieves Third Consecutive Month Of Record Market Share In January

Marijuana producer Decibel Cannabis Company Inc. (TSXV:DB) (OTCQB: DBCCF) provided an update on its recent Canadian recreational market share.

Benzinga

Jones Soda Acquires Pinestar Gold, Completes Concurrent Financings To Support Its Expansion Into Cannabis

Craft beverages distributor Jones Soda Co. (OTCQB: JSDA) has completed the previously announced acquisition of Pinestar Gold Inc., by way of a plan of arrangement under the Business Corporations Act.

Benzinga

CordovaCann Opens 14th Star Buds Cannabis Co. Store In Canada

Cannabis-focused consumer products company CordovaCann Corp. (CSE:CDVA)(OTCQB: LVRLF) opened its 14th Star Buds Cannabis Co.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Cannabis Dispensary Roundup: Cresco Labs, Body And Mind, Ayr Wellness, Green Thumb, Columbia Care, Trulieve

Body and Mind Debuts In Michigan With New Store Cannabis operator Body and Mind Inc. (CSE: BAMM) (OTCQB: BMMJ) recently received all licenses and approvals to open a Body and Mind branded dispensary in Muskegon, Michigan.

Benzinga

Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient

Psychedelics biotech startup Entheon Biomedical (CSE: ENBI) (OTCQB: ENTBF) announced the approval by the local Dutch ethics committee for a Phase 1 clinical trial evaluating the pharmacokinetics, pharmacodynamics and safety profile of the psychedelic compound DMT.

Benzinga

Cannabis Company Body And Mind Expands To Michigan

Body and Mind Inc. (CSE:BAMM) (OTCQB: BMMJ) announced completion of the first stage of the vertical strategy to expand into the rapidly growing Michigan market.

People

Spencer Cox

134 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Psychedelic Spotlight

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.